Balyasny Asset Management’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.49M Sell
40,328
-1,077,388
-96% -$103M ﹤0.01% 1528
2025
Q4
$107M Buy
1,117,716
+125,398
+13% +$12.2M 0.14% 165
2025
Q3
$94.5M Sell
992,318
-1,534,672
-61% -$141M 0.12% 187
2025
Q2
$220M Buy
2,526,990
+1,940,197
+331% +$165M 0.33% 46
2025
Q1
$52.7M Buy
586,793
+525,155
+852% +$47M 0.09% 281
2024
Q4
$4.92M Sell
61,638
-111,911
-64% -$9.69M 0.01% 1296
2024
Q3
$15.6M Buy
+173,549
New +$14.6M 0.03% 743
2023
Q3
Sell
-1,489,800
Closed -$131M 2540
2023
Q2
$131M Buy
1,489,800
+1,473,888
+9,263% +$127M 0.29% 62
2023
Q1
$1.28M Sell
15,912
-656,599
-98% -$53.5M ﹤0.01% 1646
2022
Q4
$52.3M Buy
672,511
+621,595
+1,221% +$50.4M 0.14% 181
2022
Q3
$4.11M Sell
50,916
-1,162,482
-96% -$104M 0.01% 1102
2022
Q2
$109M Buy
+1,213,398
New +$123M 0.35% 38
2022
Q1
Sell
-264,894
Closed -$27.4M 2694
2021
Q4
$27.4M Buy
+264,894
New +$30.7M 0.09% 292
2021
Q2
Sell
-539,447
Closed -$67.7M 2189
2021
Q1
$63.7M Sell
539,447
-35,381
-6% -$4.15M 0.31% 62
2020
Q4
$67.3M Sell
574,828
-284,315
-33% -$31.3M 0.37% 47
2020
Q3
$89.3M Buy
859,143
+576,553
+204% +$57.9M 0.65% 11
2020
Q2
$25.9M Buy
282,590
+67,577
+31% +$6.48M 0.22% 118
2020
Q1
$19.4M Sell
215,013
-667,494
-76% -$71M 0.23% 126
2019
Q4
$100M Buy
882,507
+149,487
+20% +$16.4M 0.6% 23
2019
Q3
$79.6M Buy
733,020
+131,861
+22% +$13.8M 0.55% 24
2019
Q2
$58.5M Buy
601,159
+520,380
+644% +$47.5M 0.37% 52
2019
Q1
$7.36M Sell
80,779
-1,011,885
-93% -$90.6M 0.05% 468
2018
Q4
$99.4M Sell
1,092,664
-7,129
-0.6% -$666K 0.72% 16
2018
Q3
$108M Buy
1,099,793
+58,278
+6% +$5.39M 0.49% 22
2018
Q2
$89.2M Sell
1,041,515
-669,924
-39% -$56M 0.4% 42
2018
Q1
$137M Buy
1,711,439
+752,483
+78% +$62.1M 0.57% 20
2017
Q4
$77.4M Buy
958,956
+946,652
+7,694% +$75.8M 0.24% 92
2017
Q3
$957K Sell
12,304
-568,783
-98% -$47.2M ﹤0.01% 1175
2017
Q2
$51.6M Buy
581,087
+429,383
+283% +$36.2M 0.21% 117
2017
Q1
$12.2M Sell
151,704
-325,176
-68% -$25.4M 0.06% 424
2016
Q4
$34M Buy
476,880
+386,880
+430% +$30.4M 0.18% 147
2016
Q3
$7.78M Sell
90,000
-707,149
-89% -$61.6M 0.05% 437
2016
Q2
$69.2M Buy
+797,149
New +$64.5M 0.45% 39
2015
Q4
Sell
-50,000
Closed -$3.35M 1355
2015
Q3
$3.35M Sell
50,000
-50,760
-50% -$3.74M 0.02% 588
2015
Q2
$7.47M Buy
+100,760
New +$7.7M 0.05% 486
2014
Q4
Sell
-582,414
Closed -$36.1M 777
2014
Q3
$36.1M Sell
582,414
-330,006
-36% -$21M 0.28% 76
2014
Q2
$58.2M Buy
+912,420
New +$55.4M 0.66% 22
2014
Q1
Sell
-334,900
Closed -$19.2M 622
2013
Q4
$19.2M Buy
+334,900
New +$19M 0.25% 108
2013
Q3
Sell
-80,260
Closed -$4.13M 659
2013
Q2
$4.13M Buy
+80,260
New +$3.97M 0.07% 334

Other funds holding MDT

Balyasny Asset Management's MDT Position: Q1 2026 in Review

Balyasny Asset Management reduced its Medtronic (MDT) stake by 96% in Q1 2026, selling an estimated $103M and leaving 40,328 shares worth $3.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Balyasny Asset Management first reported a position in MDT in Q2 2013 and has held it in 39 quarters since. The position peaked at $220M in Q2 2025. 2,229 funds tracked by Wall St. Rank hold MDT as of Q1 2026.

  • Balyasny Asset Management held 40,328 shares of Medtronic worth $3.49M as of Q1 2026.
  • Balyasny Asset Management sold 1,077,388 Medtronic shares in Q1 2026, an estimated $103M.
  • Medtronic made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1528 holding.
  • Balyasny Asset Management first reported a position in Medtronic in Q2 2013 and has held it in 39 quarters since.
  • Balyasny Asset Management's Medtronic position peaked at $220M in Q2 2025.
  • 2,229 funds tracked by Wall St. Rank held Medtronic as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.